IGUCHI KIMI - 04 Jan 2023 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role: CFO & Treasurer
Signature: /s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Kimi Iguchi
Issuer symbol: SAGE
Transactions as of: 04 Jan 2023
Net transactions value: +$2,448
Form type: 4
Filing time: 05 Jan 2023, 15:30:11 UTC
Previous filing: 18 Feb 2022
Next filing: 11 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SAGE	Common Stock	Options Exercise	$2,448	+1,800	+3.2%	$1.36	58,024	04 Jan 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SAGE	Stock Option (Right to Buy)	Options Exercise	$0	-1,800	-20%	$0.000000	7,242	04 Jan 2023	Common Stock	1,800	$1.36	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects beneficial ownership balance which includes 427 shares purchased on June 30, 2022 and 197 shares purchased on December 31, 2022, each under the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan.
F2	The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2011 Stock Option and Incentive Plan. The option vested in full on July 23, 2016.